Medpace Holdings, Inc. (MEDP) Free Cash Flow CAGR:36.40%(TTM)
Free cash flow CAGR uses precomputed cash-flow statement history.
Over longer horizons, Medpace Holdings, Inc.'s Free Cash Flow CAGR averages 24.23% over 3 years and 25.76% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Free cash flow CAGR measures how Medpace Holdings, Inc.'s cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
MEDP Free Cash Flow CAGR Chart
Medpace Holdings, Inc. (MEDP)
MEDP Quarterly Free Cash Flow Growth (YoY)
Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
MEDP Free Cash Flow CAGR History
| Year | Start FCF | End FCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $572.27M | $681.87M | +$109.60M | +19.15% | +19.15% |
| 2024 | $396.73M | $572.27M | +$175.54M | +44.25% | +44.25% |
| 2023 | $351.17M | $396.73M | +$45.55M | +12.97% | +12.97% |
| 2022 | $235.06M | $351.17M | +$116.11M | +49.40% | +49.40% |
| 2021 | $227.34M | $235.06M | +$7.72M | +3.40% | +3.40% |
| 2020 | $183.96M | $227.34M | +$43.38M | +23.58% | +23.58% |
| 2019 | $140.56M | $183.96M | +$43.40M | +30.87% | +30.87% |
| 2018 | $85.09M | $140.56M | +$55.47M | +65.19% | +65.19% |
| 2017 | $78.19M | $85.09M | +$6.90M | +8.82% | +8.82% |
| 2016 | $79.41M | $78.19M | $-1.21M | -1.52% | -1.52% |
| 2015 | $69.89M | $79.41M | +$9.52M | +13.62% | +13.62% |
| 2014 | $93.58M | $69.89M | $-23.69M | -25.32% | -25.32% |
Quarterly Free Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $144.97M | -22.9% | +25.1% |
| Q4 2025 | $188.12M | -28.3% | +2.8% |
| Q3 2025 | $262.32M | +84.2% | +89.3% |
| Q2 2025 | $142.41M | +22.9% | +37.6% |
| Q1 2025 | $115.84M | -36.7% | -21.3% |
| Q4 2024 | $183.02M | +32.1% | +25.0% |
| Q3 2024 | $138.54M | +33.8% | +31.1% |
| Q2 2024 | $103.53M | -29.7% | +39.8% |
| Q1 2024 | $147.18M | +0.5% | +108.6% |
| Q4 2023 | $146.41M | +38.5% | +14.9% |
| Q3 2023 | $105.68M | +42.7% | +4.3% |
| Q2 2023 | $74.07M | +5.0% | -13.3% |
| Q1 2023 | $70.56M | -44.6% | +90.7% |
| Q4 2022 | $127.44M | +25.8% | +106.3% |
| Q3 2022 | $101.31M | +18.6% | +54.2% |
| Q2 2022 | $85.42M | +130.9% | +50.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle